Prognostic Factors for Survival With Gemcitabine Plus 5-fluorouracil Based Regimens for Metastatic Renal Cancer
Author:
Affiliation:
1. From the Section of Hematology/Oncology (WMS, CG, CWR, TMZ, NJV), and Departments of Health Sciences (DH, TK) and Pathology (XY), University of Chicago, Chicago, Illinois
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference20 articles.
1. Systemic therapy for renal cell carcinoma;Motzer;J Urol,2000
2. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer;Yang;Proc Amer Soc Clin Oncol,2002
3. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies;Mani;Cancer,2001
4. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer;Rini;J Clin Oncol,2000
5. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma;Ryan;Cancer,2002
Cited by 81 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Sunitinib in the treatment of advanced renal cell carcinoma;Meditsinskiy sovet = Medical Council;2023-07-31
2. Patient‐derived renal cell carcinoma organoids for personalized cancer therapy;Clinical and Translational Medicine;2022-07
3. Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer;Nuclear Oncology;2022
4. Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer;Nuclear Oncology;2022
5. Diagnostic Applications of Nuclear Medicine: Kidney and Bladder Cancer;Nuclear Oncology;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3